# Figure S1




**Figure S1**. Representative intact cell MALDI-ToF mass spectrometry analysis spectra of the cell line UKF-NB-3 and its drug-adapted sublines. Some characteristic differences are highlighted in the red boxes.

# Figure S2


IMR-5
IMR-5rCDDP1000
IMR-5rVCR10
IMR-5rVINB20
IMR-5rDACARB40
IMR-5rDOCE20
Intens. [a.u.]
x10^4
m/z
10000
20000
30000
40000
50000

**Figure S2**. Representative intact cell MALDI-ToF mass spectrometry analysis spectra of the cell line IMR-5 and its drug-adapted sublines. Some characteristic differences are highlighted in the red boxes.

**Figure S3**


Intens. [a.u.]
IMR-32
IMR-32rMEL500
IMR-32rOXALI800
IMR-32rTOPO8
IMR-32rCARBO1000
m/z

**Figure S3**. Representative intact cell MALDI-ToF mass spectrometry analysis spectra of the cell line IMR-32 and its drug-adapted sublines. Some characteristic differences are highlighted in the red boxes.

# Figure S4


Samples/Scores Plot
IMR-32
IMR-5
UKF-NB-3
95% Confidence Level
Scores on PC 1 (97.08%)
Scores on PC 2 (1.46%)
Scores on PC 3 (0.59%)
x 10^4
x 10^5

**Figure S4**. Comparison of intact cell MALDI-ToF mass spectrometry analysis data derived from the cell lines IMR-32, IMR-5, and UKF-NB-3 by principal component (PC) analysis. The comparisons PC1 vs. PC2, PC1 vs. PC3, and PC2 vs. PC3 are presented.

# Figure S5


Samples/Scores Plot
x 10^4
UKF-NB-3
UKF-NB-3rCDDP1000
UKF-NB-3rOXALI2000
95% Confidence Level
Scores on PC 2 (3.30%)
Scores on PC 1 (93.89%)
x 10^4


Samples/Scores Plot
UKF-NB-3
UKF-NB-3rCDDP1000
UKF-NB-3rOXALI2000
95% Confidence Level
Scores on PC 3 (1.05%)
Scores on PC 1 (93.89%)
x 10^4


Samples/Scores Plot
UKF-NB-3
UKF-NB-3rCDDP1000
UKF-NB-3rOXALI2000
95% Confidence Level
Scores on PC 3 (1.05%)
Scores on PC 2 (3.30%)
x 10^4

**Figure S5**. Comparison of intact cell MALDI-ToF mass spectrometry analysis data derived from the cell line UKF-NB-3 and its drug-adapted sublines by principal component (PC) analysis. The comparisons PC1 vs. PC2, PC1 vs. PC3, and PC2 vs. PC3 are presented.

# Figure S6


Samples/Scores Plot
x 10^4
Scores on PC 2 (2.10%)
Scores on PC 1 (95.90%)
x 10^5
IMR-32
IMR-32rCARBO1000
IMR-32rMEL500
IMR-32rOXALI800
IMR-32rTOPO8
95% Confidence Level


Samples/Scores Plot
x 10^4
Scores on PC 3 (0.58%)
Scores on PC 1 (95.90%)
x 10^5
IMR-32
IMR-32rCARBO1000
IMR-32rMEL500
IMR-32rOXALI800
IMR-32rTOPO8
95% Confidence Level


Samples/Scores Plot
x 10^4
Scores on PC 3 (0.58%)
Scores on PC 2 (2.10%)
x 10^4
IMR-32
IMR-32rCARBO1000
IMR-32rMEL500
IMR-32rOXALI800
IMR-32TOPO8
95% Confidence Level

**Figure S6**. Comparison of intact cell MALDI-ToF mass spectrometry analysis data derived from the cell line IMR-32 and its drug-adapted sublines by principal component (PC) analysis. The comparisons PC1 vs. PC2, PC1 vs. PC3, and PC2 vs. PC3 are presented.

# Figure S7


Samples/Scores Plot
x 10^4
Scores on PC 2 (2.79%)
Scores on PC 1 (93.56%)
x 10^5
IMR-5
IMR-5rCDDP1000
IMR-5rDACARB40
IMR-5rDOCE20
IMR-5rVINB20
IMR-5rVCR10
95% Confidence Level


Samples/Scores Plot
x 10^4
Scores on PC 3 (1.19%)
Scores on PC 1 (93.56%)
x 10^5
IMR-5
IMR-5rCDDP1000
IMR-5rDACARB40
IMR-5rDOCE20
IMR-5rVINB20
IMR-5rVCR10
95% Confidence Level


Samples/Scores Plot
x 10^4
Scores on PC 3 (1.19%)
Scores on PC 2 (2.79%)
x 10^4
IMR-5
IMR-5rCDDP1000
IMR-5rDACARB40
IMR-5rDOCE20
IMR-5rVINB20
IMR-5rVCR10
95% Confidence Level

**Figure S7**. Comparison of intact cell MALDI-ToF mass spectrometry analysis data derived from the cell line IMR-5 and its drug-adapted sublines by principal component (PC) analysis. The comparisons PC1 vs. PC2, PC1 vs. PC3, and PC2 vs. PC3 are presented.

**Table S1**. Short tandem repeat (STR) profiles of project cell lines**. Loci that differ from those of the parental cell line are highlighted in yellow.**

| Cell line | D5 | D5' | D13 | D13' | D7 | D7' | D16 | D16' | vWA | vWA' | TH01 | TH01' | TPOX | TPOX' | CSF1 | CSF1' | Amel | Amel' |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UKF-NB-3* | 11 | 11 | 11 | 11 | 10 | 11 | 13 | 13 | 15 | 18 | 9 | 9.3 | 8 | 8 | 10 | 11 | X | X |
| UKF-NB-3rCDDP1000 | 11 | 11 | 11 | 11 | 10 | 11 | 13 | 13 | 15 | 18 | 9 | 9.3 | 8 | 8 | 10 | 11 | X | X |
| UKF-NB-3rOXALI2000 | 11 | 11 | 11 | 11 | 10 | 11 | 13 | 13 | 15 | 18 | 9 | 9.3 | 8 | 8 | 10 | 11 | X | X |
| | | | | | | | | | | | | | | | | | | |
| | D5 | D5' | D13 | D13' | D7 | D7' | D16 | D16' | vWA | vWA' | TH01 | TH01' | TPOX | TPOX' | CSF1 | CSF1' | Amel | Amel' |
| IMR-32 reference* | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-32 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-32rCARBO1000 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | X |
| IMR-32rMEL500 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-32rOXALI800 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 13 | X | Y |
| IMR-32rTOPO8 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| | | | | | | | | | | | | | | | | | | |
| | D5 | D5' | D13 | D13' | D7 | D7' | D16 | D16' | vWA | vWA' | TH01 | TH01' | TPOX | TPOX' | CSF1 | CSF1' | Amel | Amel' |
| IMR-5 reference* | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-5 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-5rCDDP1000 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-5rDACARB40 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | X |
| IMR-5rDOCE20 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |
| IMR-5rVINB20 | 11 | 12 | 9 | 9 | 9 | 9 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | X |
| IMR-5rVCR10 | 11 | 12 | 9 | 9 | 9 | 10 | 8 | 8 | 15 | 15 | 7 | 9.3 | 11 | 11 | 11 | 12 | X | Y |

* references: UKF-NB-3, no reference available in databases; IMR-32, DSMZ (ACC 165); IMR-5, D5-Amel (Sanger Institute)/ D3-D2 (indicated in grey)

DSMZ (ACC 165)

**Table S1**. Short tandem repeat (STR) profiles of project cell lines**. Loci that differ from those of the parental cell line are highlighted in yellow.**

| Cell line | D3 | D3` | D21 | D21` | D18 | D18` | PentaE | PentaE` | PentaD | PentaD` | D8 | D8` | FGA | FGA` | D19 | D19` | D2 | D2` |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UKF-NB-3* | 15 | 18 | 29 | 33.2 | 16 | 18 | 12 | 12 | 8 | 15 | 9 | 10 | 19 | 25 | 14 | 14 | 16 | 21 |
| UKF-NB-3rCDDP1000 | 15 | 18 | 29 | 33.2 | 16 | 18 | 12 | 12 | 8 | 15 | 9 | 10 | 19 | 25 | 14 | 14 | 16 | 21 |
| UKF-NB-3rOXALI2000 | 15 | 18 | 29 | 33.2 | 16 | 18 | 12 | 12 | 8 | 15 | 9 | 10 | 19 | 25 | 14 | 14 | 16 | 21 |
| | | | | | | | | | | | | | | | | | | |
| | D3 | D3` | D21 | D21` | D18 | D18` | PentaE | PentaE` | PentaD | PentaD` | D8 | D8` | FGA | FGA` | D19 | D19` | D2 | D2` |
| IMR-32 reference* | 16 | 16 | 30 | 31 | 12 | 15 | 7 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-32 | 16 | 16 | 30 | 31 | 12 | 15 | 7 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-32rCARBO1000 | 16 | 16 | 30 | 31 | 12 | 15 | 7 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-32rMEL500 | 16 | 16 | 30 | 31 | 12 | 15 | 7 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-32rOXALI800 | 16 | 17 | 30 | 31 | 12 | 15 | 7 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-32rTOPO8 | 16 | 16 | 30 | 31 | 12 | 15 | 15 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| | | | | | | | | | | | | | | | | | | |
| | D3 | D3` | D21 | D21` | D18 | D18` | PentaE | PentaE` | PentaD | PentaD` | D8 | D8` | FGA | FGA` | D19 | D19` | D2 | D2` |
| IMR-5 reference* | 16 | 16 | 30 | 31 | 12 | 15 | 7 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-5 | 16 | 16 | 30 | 31 | 12 | 15 | 15 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-5rCDDP1000 | 16 | 16 | 30 | 31 | 12 | 12 | 15 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-5rDACARB40 | 16 | 16 | 30 | 31 | 12 | 12 | 15 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-5rDOCE20 | 16 | 16 | 30 | 32 | 12 | 15 | 15 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |
| IMR-5rVINB20 | 16 | 16 | 30 | 31 | 15 | 15 | 15 | 15 | 11 | 12 | 13 | 13 | 24 | 24 | 14 | 15 | 23 | 24 |
| IMR-5rVCR10 | 16 | 16 | 30 | 31 | 12 | 15 | 15 | 15 | 11 | 12 | 13 | 13 | 21 | 24 | 14 | 15 | 23 | 24 |

* references: UKF-NB-3, no reference available in databases; IMR-32, DSMZ (ACC 165); IMR-5, D5-Amel (Sanger Institute)/ D3-D2 (indicated in grey)

DSMZ (ACC 165)